Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02100657
Recruitment Status : Completed
First Posted : April 1, 2014
Results First Posted : October 12, 2020
Last Update Posted : October 12, 2020
Sponsor:
Information provided by (Responsible Party):
PharmaMar

Brief Summary:
Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Plitidepsin Drug: Bortezomib Drug: Dexamethasone Phase 1

Detailed Description:
Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM), to determine the efficacy of the combination plitidepsin/bortezomib/dexamethasone, to evaluate the safety and tolerability of the combination in patients with relapsing and/or refractory MM and to study the pharmacokinetics (PK) and pharmacodynamics (PDy) of plitidepsin in combination with bortezomib and dexamethasone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Study Start Date : June 2014
Actual Primary Completion Date : June 2018
Actual Study Completion Date : June 2018


Arm Intervention/treatment
Experimental: plitidepsin + bortezomib + dexamethasone

Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).

Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.

Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk

Drug: Plitidepsin
Drug: Bortezomib
Drug: Dexamethasone



Primary Outcome Measures :
  1. Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone [ Time Frame: After 28-day cycle ]
    To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM). To define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.

  2. Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone [ Time Frame: After 28-day cycle ]
    To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM). To define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.

  3. Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib [ Time Frame: After 28-day cycle ]
    To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM). To define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.

  4. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) [ Time Frame: After 28-day cycle ]

    DLTs were defined as:

    Hematological Toxicity

    • Grade 3/4 neutropenia associated with fever or lasting>7 days related to the study treatment
    • Grade 3/4 thrombocytopenia accompanied by grade 3/4 hemorrhage
    • Extensive bone marrow (BM) infiltration, DLT was defined as grade 4 thrombocytopenia with grade 3/4 hemorrhage or grade 4 neutropenia lasting >7 days or with fever Non-hematological Toxicity
    • Grade 3/4 nausea and vomiting refractory to antiemetic therapy
    • Grade≥3 muscular Adverse events (AE) (myalgia, muscular weakness, muscle cramps, myopathy)
    • Grade≥3 alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) lasting more than 1 week
    • Grade≥3 bilirubin increase
    • Grade≥3 creatine phosphokinase (CPK) increase
    • Cardiac toxicity

      • Symptomatic or treatment-requiring grade ≥1 cardiac arrhythmia related to plitidepsin
      • Grade≥1 left ventricular systolic dysfunction related to plitidepsin
    • Neuropathic pain and peripheral sensory neuropathy related to BTZ


Secondary Outcome Measures :
  1. Response According to International Myeloma Working Group Criteria [ Time Frame: Response or disease progression was assessed on Day 1 of each cycle, assessed up to 4 years ]
    Stringent complete response (sCR) normal Free Light Chains (FLC) ratio. No clonal cells Complete response (CR) no serum/urine M-protein, no evidence of soft tissue plasmacytoma. <5% clonal plasma cells Very good partial response (VGPR) serum and urine M-protein detectable but not electrophoresis or >90% reduction in serum M-protein and urine M-protein <100 mg/24h Partial response (PR) ≥50% reduction in serum M-protein and 90% reduction in 24h urine M-protein or to <200 mg/24h. 50% reduction in size of any soft tissue plasmacytomas Minor response (MR) 25%-49% reduction of serum M-protein and 50-89% reduction of 24h urine M-protein. 25-49% reduction in size of soft tissue plasmacytomas. No increase in size or number of bone lesions Stable disease (SD) No sCR, CR, VGPR, PR, MR or PD Progressive disease (PD) 25% increase from the lowest value: serum M-protein, urine M-protein, BM plasma cell. Increase in size, new bone lesions, soft tissue plasmacytomas or serum calcium >11.5 mg/dL

  2. Overall Response Rate [ Time Frame: Response or disease progression was assessed on Day 1 of each cycle, assessed up to 4 years ]
    Overall response rate (ORR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR) according to the International Myeloma Working Group (IMWG) criteria

  3. Duration of Response [ Time Frame: From the date of the first documentation of response to the date of PD or further therapy or death, up to 4 years ]
    Duration of response (DR) was analyzed for all patients in whom a response had been observed and was calculated from the date of the first documentation of response to the date of PD or further therapy or death

  4. Time to Progression [ Time Frame: From the date of the first infusion to the date of documented PD or death due to PD, up to 4 years ]
    Time to progression (TTP) was calculated from the date of the first infusion to the date of documented PD or death due to PD.

  5. Time to Progression Rates [ Time Frame: From the date of the first infusion to the date of documented PD or death due to PD, up to 4 years ]
    Time to progression (TTP) was calculated from the date of the first infusion to the date of documented PD or death due to PD.

  6. Progression-free Survival [ Time Frame: from the date of the first infusion to the date of documented PD or death, up to 4 years ]
    Progression-free survival (PFS) was calculated from the date of the first infusion to the date of documented PD or death (regardless of the reason), whichever comes first

  7. Progression-free Survival Rates [ Time Frame: From the date of the first infusion to the date of documented PD or death, up to 4 years ]
    Progression-free survival (PFS) was calculated from the date of the first infusion to the date of documented PD or death (regardless of the reason), whichever comes first

  8. Event-free Survival [ Time Frame: From the date of first infusion to the date of documented PD or death, up to 4 years ]
    Event-free survival (EFS) was calculated from the date of first infusion to the date of documented PD or death, but could include additional events besides death and PD that were considered of importance

  9. Event-free Survival Rates [ Time Frame: from the date of first infusion to the date of documented PD or death, up to 4 years ]
    Event-free survival (EFS) was calculated from the date of first infusion to the date of documented PD or death, but could include additional events besides death and PD that were considered of importance



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years.
  • Prior autologous transplantation (HSCT) patients are allowed.
  • Patients must have received at least one previous treatment line of induction, chemotherapy, chemotherapy and transplantation or previous treatment with bortezomib or another proteasome drug

Exclusion Criteria:

  • Previous treatment with plitidepsin.
  • Active or metastatic primary malignancy other than MM.
  • Serious concomitant systemic disorders
  • History of hypersensitivity reactions to bortezomib, polyoxyl 35 castor oil or mannitol
  • Neuropathy
  • Pregnant and/or lactating women
  • HIV infection
  • Active hepatitis B or C virus infection.
  • Treatment with any Investigational Medicinal Product (IMP) in the 30 days before inclusion in the study
  • Plasma cell leukemia at the time of study entry
  • Contraindication for the use of steroids

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02100657


Locations
Layout table for location information
France
Institut Gustave Roussy
Villejuif, France, 94805
Spain
Hospital Universitario Germans Trias I Pujol
Badalona, Barcelona, Spain, 08916
Clínica Universidad de Navarra
Pamplona, Navarra, Spain, 31008
MD Anderson Cancer Center Madrid
Madrid, Spain, 28033
Hospital Universitario Salamanca
Salamanca, Spain, 37007
Hospital Universitario Virgen del Rocío
Sevilla, Spain, 41013
Hospital Universitari i Politècnic la Fe
Valencia, Spain, 46026
Sponsors and Collaborators
PharmaMar
  Study Documents (Full-Text)

Documents provided by PharmaMar:
Study Protocol  [PDF] October 8, 2015
Statistical Analysis Plan  [PDF] April 22, 2016

Layout table for additonal information
Responsible Party: PharmaMar
ClinicalTrials.gov Identifier: NCT02100657    
Other Study ID Numbers: APL-A-012-13
First Posted: April 1, 2014    Key Record Dates
Results First Posted: October 12, 2020
Last Update Posted: October 12, 2020
Last Verified: September 2020
Keywords provided by PharmaMar:
multiple myeloma
plitidepsin
APLIDIN
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Bortezomib
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents